Methadone

A substrate and mechanism-based inhibitor of CYP19 (aromatase)

Wenjie Jessie Lu, Robert Bies, Landry K. Kamden, Zeruesenay Desta, David A. Flockhart

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The peripheral conversion of testosterone to estradiol by aromatase is the primary source of endogenous estrogen in postmenopausal women. Studies indicating that placental aromatase is able to metabolize methadone to its primary metabolite, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidin (EDDP), led us to test the hypothesis that methadone is able to act as an inhibitor of aromatase. Using recombinant human CYP19, we examined the ability of methadone to bring about either reversible or mechanism-based inhibition of the conversion of testosterone to estradiol. To test for reversible inhibition, racemic methadone or its metabolite EDDP or 2-ethyl-5-methyl-3, 3-diphenylpyrroline (EMDP) was incubated for 30 min with testosterone at the K m (4 μM). To test for mechanism-based inhibition, microsomal preincubations were performed for up to 30 min using racemic methadone (1-1000 μM), R- or S-methadone (0.5-500 μM), or EDDP or EMDP (10 and 100 μM) followed by incubation with testosterone at a V max concentration (50 μM). Racemic methadone, EDDP, and EMDP did not act as competitive inhibitors of CYP19. Preincubation of methadone, EDDP, or EMDP with CYP19 resulted in time- and concentrationdependent inhibition, indicating a mechanism-based reaction that destroys CYP19 activity. The K I and k inact values for racemic methadone were calculated to be 40.6 ± 2.8 μM and 0.061 ± 0.001 min -1, respectively. No stereoselectivity was observed. Methadone is metabolized by CYP19 and may act as a potent inhibitor of CYP19 in vivo. These findings may contribute to variability in methadone clearance, to drug-drug interactions, and to side effects observed in individual patients.

Original languageEnglish
Pages (from-to)1308-1313
Number of pages6
JournalDrug Metabolism and Disposition
Volume38
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Aromatase Inhibitors
Aromatase
Methadone
Testosterone
Estradiol
Drug Interactions
Estrogens

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Methadone : A substrate and mechanism-based inhibitor of CYP19 (aromatase). / Lu, Wenjie Jessie; Bies, Robert; Kamden, Landry K.; Desta, Zeruesenay; Flockhart, David A.

In: Drug Metabolism and Disposition, Vol. 38, No. 8, 08.2010, p. 1308-1313.

Research output: Contribution to journalArticle

Lu, Wenjie Jessie ; Bies, Robert ; Kamden, Landry K. ; Desta, Zeruesenay ; Flockhart, David A. / Methadone : A substrate and mechanism-based inhibitor of CYP19 (aromatase). In: Drug Metabolism and Disposition. 2010 ; Vol. 38, No. 8. pp. 1308-1313.
@article{9b34b8e4811a4c718d6c8032b6d83fc4,
title = "Methadone: A substrate and mechanism-based inhibitor of CYP19 (aromatase)",
abstract = "The peripheral conversion of testosterone to estradiol by aromatase is the primary source of endogenous estrogen in postmenopausal women. Studies indicating that placental aromatase is able to metabolize methadone to its primary metabolite, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidin (EDDP), led us to test the hypothesis that methadone is able to act as an inhibitor of aromatase. Using recombinant human CYP19, we examined the ability of methadone to bring about either reversible or mechanism-based inhibition of the conversion of testosterone to estradiol. To test for reversible inhibition, racemic methadone or its metabolite EDDP or 2-ethyl-5-methyl-3, 3-diphenylpyrroline (EMDP) was incubated for 30 min with testosterone at the K m (4 μM). To test for mechanism-based inhibition, microsomal preincubations were performed for up to 30 min using racemic methadone (1-1000 μM), R- or S-methadone (0.5-500 μM), or EDDP or EMDP (10 and 100 μM) followed by incubation with testosterone at a V max concentration (50 μM). Racemic methadone, EDDP, and EMDP did not act as competitive inhibitors of CYP19. Preincubation of methadone, EDDP, or EMDP with CYP19 resulted in time- and concentrationdependent inhibition, indicating a mechanism-based reaction that destroys CYP19 activity. The K I and k inact values for racemic methadone were calculated to be 40.6 ± 2.8 μM and 0.061 ± 0.001 min -1, respectively. No stereoselectivity was observed. Methadone is metabolized by CYP19 and may act as a potent inhibitor of CYP19 in vivo. These findings may contribute to variability in methadone clearance, to drug-drug interactions, and to side effects observed in individual patients.",
author = "Lu, {Wenjie Jessie} and Robert Bies and Kamden, {Landry K.} and Zeruesenay Desta and Flockhart, {David A.}",
year = "2010",
month = "8",
doi = "10.1124/dmd.110.032474",
language = "English",
volume = "38",
pages = "1308--1313",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "8",

}

TY - JOUR

T1 - Methadone

T2 - A substrate and mechanism-based inhibitor of CYP19 (aromatase)

AU - Lu, Wenjie Jessie

AU - Bies, Robert

AU - Kamden, Landry K.

AU - Desta, Zeruesenay

AU - Flockhart, David A.

PY - 2010/8

Y1 - 2010/8

N2 - The peripheral conversion of testosterone to estradiol by aromatase is the primary source of endogenous estrogen in postmenopausal women. Studies indicating that placental aromatase is able to metabolize methadone to its primary metabolite, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidin (EDDP), led us to test the hypothesis that methadone is able to act as an inhibitor of aromatase. Using recombinant human CYP19, we examined the ability of methadone to bring about either reversible or mechanism-based inhibition of the conversion of testosterone to estradiol. To test for reversible inhibition, racemic methadone or its metabolite EDDP or 2-ethyl-5-methyl-3, 3-diphenylpyrroline (EMDP) was incubated for 30 min with testosterone at the K m (4 μM). To test for mechanism-based inhibition, microsomal preincubations were performed for up to 30 min using racemic methadone (1-1000 μM), R- or S-methadone (0.5-500 μM), or EDDP or EMDP (10 and 100 μM) followed by incubation with testosterone at a V max concentration (50 μM). Racemic methadone, EDDP, and EMDP did not act as competitive inhibitors of CYP19. Preincubation of methadone, EDDP, or EMDP with CYP19 resulted in time- and concentrationdependent inhibition, indicating a mechanism-based reaction that destroys CYP19 activity. The K I and k inact values for racemic methadone were calculated to be 40.6 ± 2.8 μM and 0.061 ± 0.001 min -1, respectively. No stereoselectivity was observed. Methadone is metabolized by CYP19 and may act as a potent inhibitor of CYP19 in vivo. These findings may contribute to variability in methadone clearance, to drug-drug interactions, and to side effects observed in individual patients.

AB - The peripheral conversion of testosterone to estradiol by aromatase is the primary source of endogenous estrogen in postmenopausal women. Studies indicating that placental aromatase is able to metabolize methadone to its primary metabolite, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidin (EDDP), led us to test the hypothesis that methadone is able to act as an inhibitor of aromatase. Using recombinant human CYP19, we examined the ability of methadone to bring about either reversible or mechanism-based inhibition of the conversion of testosterone to estradiol. To test for reversible inhibition, racemic methadone or its metabolite EDDP or 2-ethyl-5-methyl-3, 3-diphenylpyrroline (EMDP) was incubated for 30 min with testosterone at the K m (4 μM). To test for mechanism-based inhibition, microsomal preincubations were performed for up to 30 min using racemic methadone (1-1000 μM), R- or S-methadone (0.5-500 μM), or EDDP or EMDP (10 and 100 μM) followed by incubation with testosterone at a V max concentration (50 μM). Racemic methadone, EDDP, and EMDP did not act as competitive inhibitors of CYP19. Preincubation of methadone, EDDP, or EMDP with CYP19 resulted in time- and concentrationdependent inhibition, indicating a mechanism-based reaction that destroys CYP19 activity. The K I and k inact values for racemic methadone were calculated to be 40.6 ± 2.8 μM and 0.061 ± 0.001 min -1, respectively. No stereoselectivity was observed. Methadone is metabolized by CYP19 and may act as a potent inhibitor of CYP19 in vivo. These findings may contribute to variability in methadone clearance, to drug-drug interactions, and to side effects observed in individual patients.

UR - http://www.scopus.com/inward/record.url?scp=77954945999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954945999&partnerID=8YFLogxK

U2 - 10.1124/dmd.110.032474

DO - 10.1124/dmd.110.032474

M3 - Article

VL - 38

SP - 1308

EP - 1313

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 8

ER -